相关实验视频
Updated: Jun 29, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.6K
开始护理:一个随机对照试验的协议,用于对儿童进行逐步的布德森-福莫特醇缓解剂治疗
Tasmin Barry1,2, Mark Holliday1, Jenny Sparks1
1Medical Research Institute of New Zealand, Wellington, New Zealand.
ERJ open research
|April 9, 2024
概括
这项研究调查了婴儿喘的布塞尼德-福莫特醇缓解疗法. 它将这种新方法与标准治疗方法进行比较,旨在确定其在年轻患者中的有效性和安全性.
科学领域:
- 儿科呼吸系统医学 儿科呼吸系统医学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘是全世界儿童的主要慢性呼吸道疾病之一.
- 吸入性皮质类固醇 (ICS) - 甲醇缓解剂疗法在成年人中表现有前途,但在儿童中需要验证.
- 对于儿童喘管理中的抗炎缓解疗法存在有限的证据.
研究的目的:
- 评估布塞尼德-福莫特醇缓解疗法的疗效和安全性,与5至11岁患有喘的儿童的标准治疗相比.
- 为了比较单独使用布西尼德-福莫特罗尔缓解剂或作为维持和缓解剂疗法 (MART),与传统的ICS或ICS-长效β-agonist (LABA) 维持与短效β-agonist (SABA) 缓解剂相比.
- 建立儿童喘管理新策略的证据基础.
主要方法:
- 这是一项为期52周的多中心,开放性,随机对照试验 (RCT),涉及400名患有不同严重程度喘的儿童 (5-11岁).
- 参与者被随机分配到单独服用布德化物-福莫特醇缓解剂或MART,或随机分配到布德化物/布德化物-福莫特醇维护剂和特尔布他林缓解剂.
- 主要结局:中度至严重喘恶化率;次要结局包括喘控制,肺功能和呼出的氧化.
主要成果:
- 这个部分不在所提供的摘要中.
结论:
- 这项研究代表了第一个比较布索尼德-福莫特醇缓解剂策略与儿童常规ICS基疗法的RCT.
- 预计结果将为优化儿科患者喘治疗提供关键证据.
- 这些发现将为管理儿童喘的临床指导方针提供信息.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:23Inhaled Medications
256
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
256
01:17Drugs Used in Lower Respiratory Disorders: Overview
428
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
428
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
256
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
256
01:26COPD: Management Using Bronchodilators and Corticosteroids
198
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
198
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116